Home / Market News / $AMGN
benzinga Corporate Catalyst Impact 55/100 ● positive

UBS Maintains Buy on Amgen, Raises Price Target to $470

Oct 9, 2026, 3:29 PM UTC · Primary ticker $AMGN

UBS analyst Michael Yee has reiterated a 'Buy' rating on Amgen and increased its price target from $430 to $470. This indicates a positive outlook from a major financial institution, potentially influencing investor sentiment and the stock's short-term trading activity.

UBS analyst Michael Yee has maintained a 'Buy' rating for Amgen and raised the price target from $430 to $470. This action signals increased confidence from a prominent financial institution in Amgen's future performance and valuation. For traders, this could lead to short-term positive momentum for AMGN stock as investors react to the upgraded outlook. The long-term implications depend on whether Amgen's fundamentals align with this increased valuation, but in the short term, it presents an opportunity for those looking to capitalize on positive analyst sentiment.

$AMGN positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.